At a glance
ClinicalIndex Comparison RecordN/ACompleted· 601 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Observational, Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan) During 1 Year Among 20 and Older Diagnosed With Essential Hypertension
In Brief
An observational study for Essential Hypertension. Completed, enrolled 601 participants across 1 site.
Detailed Summary
Evaluated the incidence and characteristics of adverse events during the treatment for Kanarb tablet.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2013
First PostedMar 2015
Primary CompletionJul 2017
Study CompletionApr 2018
TodayJul 2026
First PostedMar 11, 2015
Enrollment StartMay 1, 2013
Primary CompletionJul 1, 2017
Study CompletionApr 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 11.3 years ago